ArticleDiscover oncology2026
Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe Scottish Inflammatory Prognostic Score (SIPS), derived from serum albumin and neutrophil count integrates inflammatory and nutritional status. However, its prognostic role in advanced non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors remains unclear.
methodsThis multicenter, retrospective study included 816 patients with advanced or metastatic NSCLC who received nivolumab following platinum-based chemotherapy between January 2015 and January 2025 at 19 oncology centers in Turkey. The SIPS was calculated at baseline by assigning one point each for albumin < 35 g/L and neutrophil count > 7.5 × 10⁹/L, classifying patients as favorable (0), intermediate (1), or poor (2). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier analysis and compared using the log-rank test. Cox regression models were used to identify independent prognostic factors.
resultsThe median OS decreased across the SIPS groups: 15.0 months (95% CI 12.9–17.1), 8.0 months (95% CI 5.3–10.7), and 5.0 months (95% CI 3.5–6.5) for the favorable, intermediate, and poor groups, respectively (p < 0.001). The median PFS was 7.0, 4.0, and 2.0 months (p < 0.001). In the multivariate analysis, SIPS remained independently associated with both OS (HR = 3.19, 95% CI 1.90–5.35, p < 0.001) and PFS (HR = 3.02, 95% CI 1.89–4.84, p < 0.001).
conclusionsBaseline SIPS is a simple, cost-effective, and independent prognostic biomarker in nivolumab-treated NSCLC. Prospective studies are needed to validate these findings and evaluate its integration with other markers to improve clinical risk stratification and may be useful for prognostic assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.